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Objective: Small uncontrolled series suggest that treatment of obstructive sleep apnea (OSA) in
patients with epilepsy may improve seizure control. Prior to conducting a definitive randomized
controlled trial, we addressed critical design issues in a pilot study.
Methods: We identified a cohort of adult patients with medically refractory epilepsy and coexist-
ing OSA, documented by polysomnography (PSG). After an 8-week baseline period, subjects with
OSA were randomized to therapeutic or sham continuous positive airway pressure (CPAP) for 10
weeks. Subjects maintained seizure calendars and antiepileptic drug dosages were held constant.
Results: Sixty-eight subjects with suspected OSA were enrolled and 35 subjects randomized to
therapeutic CPAP (22 subjects) or sham (13 subjects) CPAP. Male gender and an elevated sleep
apnea questionnaire score were predictive of OSA on PSG. Nineteen subjects in the therapeutic
group and all 13 subjects in the sham group completed the trial. Baseline apnea-hypopnea index
(AHI) and CPAP adherence were comparable between groups. A significant reduction in AHI was
observed in the therapeutic CPAP group as compared to the sham group. Subjects, study coordi-
nators, and principal investigators were unable to predict treatment allocation.
Conclusions: This pilot study provided critical information related to study design and feasibility
for planning a comprehensive trial to test the hypothesis that treating obstructive sleep apnea in
patients with epilepsy improves seizure control. Neurology® 2008;71:572–577
GLOSSARY
AEDs  antiepileptic drugs; AHI  apnea-hypopnea index; BMI  body mass index; CPAP  continuous positive airway
pressure; OSA  obstructive sleep apnea; PSG  polysomnography.
Epilepsy has a prevalence of 0.5–1.0%1 and 30% of affected individuals continue to have
seizures despite antiepileptic drugs (AEDs).2 Reducing factors which may promote seizures,
such as sleep deprivation,3-5 could lead to new and more effective treatment strategies.
Obstructive sleep apnea (OSA), a common disorder resulting in sleep disruption and depriva-
tion,6 is present in as many as 33% of patients with refractory partial epilepsy. 7 In older adults with
epilepsy, the presence of sleep apnea is associated with worsening seizure control or late onset
seizures.8 While several clinical series have reported improvements in seizure control after identifica-
tion and treatment of comorbid OSA,9-12 none of these studies involved randomization, double-
blind design, or the use of sham continuous positive airway pressure (CPAP) as a control condition.
A definitive clinical trial with these features could establish the importance of screening for and
treating OSA within an epilepsy population. Several unanswered questions have complicated plan-
ning such a trial, however. These include efficient identification of OSA, adherence to and blinding
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To address these questions and effectively
plan for such a definitive randomized multi-
center study, we performed a prospective, ran-
domized, double-blind, preliminary trial of
CPAP for seizure reduction in patients with
refractory epilepsy with coexisting OSA.
METHODS Screening and enrollment. This pilot clinical
trial was conducted between September 2002 and July 2005 at
University of Michigan, Cleveland Clinic, University of North
Carolina at Chapel Hill, and Vanderbilt University, with a Data
Coordinating Center at the University of Michigan. The study
was approved by each site’s Institutional Review Board and a
National Institute of Neurological Disorders and Stroke Data
Safety and Monitoring Board also oversaw conduct of the trial.
The Food and Drug Administration granted us an Investiga-
tional Device Exemption to study sham CPAP in our subjects.
Epilepsy clinic patients initially meeting trial eligibility on the
basis of chart review completed the Sleep Apnea Scale of the
Sleep Disorders Questionnaire,13 and underwent a sleep and ep-
ilepsy evaluation by the site investigator. Subjects continuing to
meet eligibility criteria (table 1, table e-1 on the Neurology® Web
site at www.neurology.org), including two or more quantifiable
partial or generalized seizures per month (excluding simple par-
tial seizures), were invited to provide informed consent to partic-
ipate in the trial. During the initial enrollment visit, subjects
were given basic sleep hygiene information, including avoiding
sleep deprivation and alcohol, and minimizing sleeping in the
supine position. Subjects were given standardized seizure calen-
dars and instructed how to tabulate each specific seizure type.
Baseline and treatment phases. After enrollment, subjects
participated in an 8-week baseline phase which included two nights
of diagnostic PSG. Those meeting study criteria for OSA by PSG
were randomized in a 2:1 ratio to either therapeutic or sham treat-
ment with CPAP using a computerized random number generator
at the Data Coordinating Center, with envelopes containing the
specified assignment (therapeutic vs sham CPAP) mailed to each
site. The sleep technologist at each site opened the randomization
envelope prior to the titration nights. Subjects then underwent two
nights of either therapeutic or sham CPAP titration, during which
subjects randomized to therapeutic CPAP were titrated to the ap-
propriate pressure that resolved their apneas and hypopneas. Those
randomized to sham CPAP slept with the sham CPAP both nights.
Our rationale for including two nights was to document an AHI on
night 2 of the therapeutic or sham titration that could be compared
with the subjects’ AHI from their baseline PSGs; as night 1 of a
titration involves attempting a variety of pressure settings in the
therapeutic group as well as adjustment of masks in both therapeutic
and sham groups, night 2 provided a clearer indicator of AHI on an
effective CPAP setting. After the two nights of titration, subjects
were given a home CPAP unit (either therapeutic or sham). Sham
CPAP methodology is described in appendix e-1 and figure e-1.
To preserve blinding, subjects were loaned CPAP machines
(Respironics REMstar Pro CPAP System, Respironics, Inc,
Murrysville, PA) and observed during a 10-week treatment
phase (2 weeks of CPAP acclimation followed by 8 additional
weeks of treatment). At the end of the study, all subjects were
placed on therapeutic CPAP (those on sham were titrated to the
appropriate pressure that resolved their apneas and hypopneas).
Subjects received a weekly phone call from the site coordinator
inquiring about adherence to CPAP and the presence of adverse
events. The study coordinators at each site were blinded to the
intervention, as were the principal site investigators and sleep
technologists who analyzed the studies for staging and respira-
tory events. The only individuals aware of the intervention were
the sleep technologists who performed the studies and a physi-
cian at each site, separate from the principal investigator, who
reviewed the results of the therapeutic CPAP titrations with the
sleep technologists prior to initiating CPAP.
Polysomnography. The PSG recordings included EEG, elec-
trooculogram, submental EMG, nasal-oral airflow, respiratory
effort, pulse oximetry, and anterior tibialis EMG. At all sites,
studies were staged according to standard criteria14 by a regis-
tered PSG technologist who was blinded to the treatment status.
Respiratory events were scored using the following criteria: an
obstructive apnea was defined by an decrease in the thermistor
channel by 90% or greater for 10 or more seconds; a hypopnea
was defined by a decrease in the nasal pressure transducer chan-
nel by 50% or greater for 10 or more seconds, associated with
Table 1 Study criteria
Inclusion criteria
Age 18 years or older.
A diagnosis of medically refractory partial or generalized
epilepsy (symptomatic or idiopathic) confirmed by the site
investigator, defined by two or more seizures per month
indicated on the survey and confirmed by chart review.
A quantifiable seizure type (subjects were aware they had
experienced a seizure or had a reliable caregiver present
most of the time who was aware that the patient
experienced a seizure). Absence, myoclonic, and other
types of seizures with a motor component were included,
but sensory simple partial seizures were excluded as
these can be difficult to quantify.
Cutoffs of 26 or higher for women or 29 or higher for men
on the Sleep Apnea Scale of the Sleep Disorders
Questionnaire (Sleep Apnea Scale of the Sleep Disorders
Questionnaire) or a compelling history supportive of OSA,
with a confirmatory evaluation by the site investigator
suggesting a high likelihood for OSA.
Subjects and their physicians agreed to have their
medication regimens optimized.
Those subjects being considered for other interventions
were offered participation in the study if they were willing to
defer their other interventions until this study is completed.
Exclusion criteria
Subjects with effectively treated OSA.
Seizures secondary to drugs, alcohol, infection, neoplasia,
demyelination, metabolic illness, or progressive
degenerative disease.
Nonepileptic spells (e.g., pseudoseizures) alone or in
combination with epileptic seizures.
Narcolepsy or another primary sleep disorder requiring
intervention with medications and potentially affecting
results of study.
History of poor compliance with AEDs.
Active treatment with the vagus nerve stimulator,
pregnancy, significant history of medical or psychiatric
disease, or alcohol or drug abuse during the 1-year period
prior to trial participation.
Evidence of medical instability (e.g., congestive heart failure,
cardiac arrhythmias, pulmonary disease) due to obstructive
sleep apnea. These patients underwent an expedited
evaluation and treatment given their clinical condition.
Greater than 10 seizures a day, as this may interfere with
polysomnography or result in apparent apneas.
Detailed criteria are provided in table e-1.
OSA  obstructive sleep apnea; AEDs  antiepileptic drugs.
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either a 3% oxygen desaturation or an EEG arousal lasting 3
seconds or longer.15 All studies were reviewed by the site investi-
gator. To further enhance the quality of the measurements and
ensure reliability among sites, one of the registered sleep technol-
ogists visited each of the other sites to review records and confirm
consistency in the scoring of sleep stages and respiratory events. To
meet eligibility for the study, an AHI of 5 or greater on at least one
night of study was required. To expedite treatment in subjects with
severe sleep apnea, we planned to exclude from randomization sub-
jects whose AHIs were greater than 50 on at least one night of study,
although no enrolled subjects met this criterion. In prior work, we
have shown that the AHI on nights 1 and 2 of study were compara-
ble.16 Therefore, we averaged the AHI from nights 1 and 2 to deter-
mine the baseline AHI for each subject.
CPAP adherence. CPAP adherence was measured using cards
built into the CPAP systems. These cards were downloaded into
a commercially available software package (Respironics, Inc.)
and provided the time used in a 4-week period.
Data collection and statistical analysis. Our analyses fo-
cused on design and feasibility issues rather than efficacy of
CPAP in reducing seizure frequency. Therefore, we did not
power our trial to have sufficient sample size to test efficacy.
Instead, we screened outpatient clinic rosters and contacted eligi-
ble subjects arriving in our epilepsy clinics to determine the ratio
of subjects screened to subjects enrolled and reasons for exclu-
sion. This information was collected to evaluate whether specific
study criteria (e.g., seizure frequency) needed to be modified to
maximize enrollment in a larger scale trial.
Data were collected on case report forms completed by site
personnel and entered electronically onto a Web-based data en-
try system with second data entry and verification by the Data
Coordinating Center. Adverse events were tabulated (table e-2).
To answer the study-related design questions stated in the
Introduction, the Mann-Whitney test (for continuous variables)
and the Mantel-Haenszel test (for categorical variables) were
used to compare groups, along with Spearman correlation to
assess the association of age with CPAP adherence. The likeli-
hood that subjects and study personnel could predict whether an
individual subject was using therapeutic or sham CPAP was as-
sessed using the Kappa statistic.
Seizure frequencies for the 8-week baseline phase and the
8-week treatment phase (after 2 weeks of acclimation) were tab-
ulated. Fisher exact test was used to compare the proportions of
subjects in each group who had obtained a greater than 50%
reduction in seizure frequency (responder rate), an established
metric in epilepsy clinical trials.17
RESULTS Subjects. We screened 865 subjects to en-
roll 68 subjects meeting criteria into the study (figure
1). The leading reason for ineligibility was not meet-
ing criteria for seizure frequency and quantification
(401 subjects), followed by not meeting the SA-SDQ
cutoffs (353 subjects). Between the time of enroll-
ment and polysomnography, 23 subjects exited from
the study. Compared to those who were retained in
the study until the PSG, these subjects did not differ
in age, gender, body mass index (BMI), SA-SDQ
score, or baseline seizure frequency.
Of 45 subjects undergoing PSG, 36 met PSG cri-
teria for OSA (80%), 35 were randomized (one was
not randomized per physician discretion), and 32
completed the study. Only three subjects discontin-
ued the intervention after randomization, all in the
therapeutic group. One subject desired admission to
an epilepsy monitoring unit for seizure localization,
necessitating medication taper. The other two sub-
jects withdrew because they found CPAP cumber-
some to use, although they did not experience any
adverse effects from the device.
Characteristics of our sample and identification of
subjects with PSG-documented OSA. The majority of
subjects had partial epilepsy, with generalized epi-
lepsy present in only seven subjects. In comparing
the 36 subjects meeting PSG criteria for OSA (AHI
 5) with the 9 subjects who did not meet PSG
criteria (table 2), only male gender and the total SA-
SDQ score were significantly higher in the subjects
with OSA. All subjects with a history of hypertension
were in the group with PSG-documented OSA, al-




(n  9) p Value
Age 41.8  12.8 37.8  13.1 0.39
Gender (male) 58% 11% 0.03
BMI (kg/m2) 32.7  8.1 31.3  7.6 0.59
History of HTN 22% 0% 0.29
Epworth Sleepiness Scale 11.5  5.6 9.33  5.3 0.33
Sleep Apnea Scale 34.3  7.3 28  6.0 0.02
Baseline seizure freq/mo 14.7  26.3 9.3  6.4 0.4
No. of AEDs* 1.9  0.6 2.0  0.9 0.7
Seizures in sleep (>50%) 32% 25% 0.98
Smoking history 50% 29% 0.81
Values presented are mean  SD or %.
*Number of antiepileptic drugs (AEDs) per subject ranged from one to three, and included
phenytoin, phenobarbital, primidone, valproate, carbamazepine, topiramate, lamotrigine, le-
vetiracetam, oxcarbazepine, and zonisamide.
OSA  obstructive sleep apnea; BMI  body mass index; HTN  hypertension.




(n  13) p Value
Age 42.7  12.3 40.2  14.3 0.52
Gender (male) 14 of 22 6 of 13 0.52
BMI 31.6  7.0 34.9  9.8 0.52
Baseline seizure freq 14.7  26.5 16.1  30.3 0.74
No. of AEDs 1.9  0.7 1.9  0.5 0.76
Baseline AHI 16.1  8.4 19.4  7.2 0.13
CPAP minutes used/night 283.4  123.9 216.4  123.5 0.26
CPAP proportion of nights used per mo 0.66  0.32 0.74  0.24 0.82
Values presented are mean  SD.
CPAP  continuous positive airway pressure; BMI  body mass index; AEDs  antiepileptic
drugs; AHI  apnea-hypopnea index.
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though the proportion of subjects with hypertension
in the two groups did not reach significance.
Effect of mode of CPAP (therapeutic vs sham) on AHI
during titration study. Subjects randomized to thera-
peutic vs sham CPAP did not differ in age, gender,
BMI, baseline seizure frequency, or AED number
(table 3). Three subjects in the sham group and none
in the therapeutic group were taking barbiturates or
benzodiazepines. The AHI on the baseline studies
did not differ in those randomized to therapeutic vs
sham CPAP. The second night of CPAP titration
demonstrated a significant reduction in the AHI in
the therapeutic group as compared to the sham
group (p  0.001; figure 2).
CPAP tolerance and adherence. Adverse events were
mild, resolved with treatment, and did not result in
study discontinuation (details in supplemental data).
Overall, the proportion of nights that subjects used
CPAP was 0.68  0.30, with average minutes used
per night of 265.4  125 (4.4 hours). Adherence was
similar in the therapeutic and sham groups (table 3).
Older age was associated with increased nightly min-
utes of CPAP use (r  0.57; p  0.002). Subjects 45
years of age and older used their CPAP for 311.1 
135.2 minutes/night as opposed to 219.7  98.8
minutes/night in the younger subjects (p  0.07).
Percentage of nights CPAP was used did not corre-
late with age. Gender did not influence CPAP use.
Blinding. The likelihood of any group to predict
whether a subject was receiving treatment with ther-
apeutic vs sham CPAP after accounting for chance
was only in the fair range for subjects (kappa 
0.30), study coordinators (kappa  0.36), and prin-
cipal site investigators (kappa  0.30).
Effect of therapeutic vs sham CPAP on seizure fre-
quency. A 50% or greater reduction in seizures was
observed in 28% of the subjects in the therapeutic
group as compared to 15% of those in the sham
group, although this result was not statistically signif-
icant (p  0.40). Four subjects treated with thera-
peutic CPAP and one subject treated with sham
CPAP became seizure-free. Two of the subjects
treated with therapeutic CPAP who had a 50% or
greater reduction in seizures had mild sleep apnea,
both with baseline AHIs of 5.2 events/hour. Based
on these results, in a definitive trial, 150 subjects in
each group (therapeutic and sham) would be needed
to detect a 13% reduction in seizures, using a 2 test
at 0.05 significance level and 80% power.
DISCUSSION Our major findings from this pilot
study were as follows: 1) subjects could be success-
fully screened for the trial as evidenced by a high
proportion of patients having PSG-documented
OSA; 2) subjects given therapeutic and sham CPAP
were able to remain in the trial to completion, with
Figure 1 Flow diagram showing screening, enrollment, randomization, and
follow-up of subjects
Figure 2 Reduction in apnea-hypopnea index
(AHI) between baseline and
titration studies
Subjects in the therapeutic continuous positive airway
pressure (CPAP) group showed a significant reduction in
AHI (reduced to 3.1  2.4 events/hour on CPAP from
16.1  8.4 events/hour at baseline) as compared to the
sham group (reduced to 18.0  14.9 events/hour on
CPAP from 19.4  7.1 events/hour at baseline). The AHI
difference on CPAP in the therapeutic and sham CPAP
groups was significant (p  0.0001).
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few dropouts; 3) sham CPAP functioned as an effec-
tive blinding modality, in that the AHI was not re-
duced in subjects given this modality as compared to
those who were titrated with therapeutic CPAP; 4)
subjects and study personnel could not consistently
distinguish sham from therapeutic CPAP use; 5) sub-
jects treated with therapeutic vs sham CPAP used
their devices a similar number of hours/night, with
older subjects showing the highest adherence to
CPAP; and 6) treatment was associated with few ad-
verse events, which were mild, resolvable, and did
not lead to study discontinuation (the two subjects
who discontinued CPAP did so because it was cum-
bersome to use). We were also able to demonstrate
that we could conduct a study involving complex
and multiple procedures, including sham CPAP,
across sites and estimate the magnitude of the poten-
tial effect on seizure reduction that we might expect
to find in a large scale RCT. A summary of response
to AED treatment in medically refractory epilepsy
has documented comparable responder rates to ours
for active and placebo treatment with AEDs.17
Higher SA-SDQ scores were more likely to be
associated with PSG-associated OSA, as was male
gender. Of interest, the level of subjective daytime
sleepiness was not associated with having PSG-
associated OSA, perhaps because patients with epi-
lepsy may be sleepy for a variety of reasons (e.g.,
seizures, AED use). Prior studies have shown that
adult subjects can be successfully identified as having
PSG-documented OSA by using screening question-
naires that assessed age, sex, BMI,13,18,19 and, in some
instruments, daytime sleepiness.20-22 We previously
showed that, in an epilepsy-specific population, the
SA-SDQ was a useful screening instrument for
OSA.23
BMI was not associated with having PSG-
associated OSA. This may reflect that other factors
are more tightly associated with having PSG-
associated OSA than BMI in the epilepsy population,
or that our sample included subjects with a relatively
high BMI (the BMI was 30 kg/m2 in the group with
and without PSG-associated OSA; table 2).
Sham CPAP has been used in prior trials involv-
ing subjects with OSA24-26 as well as in ongoing tri-
als.27 However, with the exception of one study using
sham noninvasive ventilation in patients with amyo-
trophic lateral sclerosis,26 ours is the only trial to 1)
focus on patients with a neurologic disorder, and 2)
document that subjects could be blinded to treat-
ment received. Our trial also confirmed that sham
CPAP does not significantly lower AHI compared to
baseline, while therapeutic CPAP does, as had been
shown in prior reports.28-30 As in other trials, subjects
treated with sham CPAP did not differ in adherence
measures from those treated with therapeutic CPAP.
In contrast to the expectation that patients with a
neurologic disorder might show diminished CPAP
adherence in comparison to that reported for other
groups, our subjects were adherent with CPAP at
rates comparable to these other clinical studies, with
CPAP used, on average, 68% of nights and 4.4 hours
per night. Older adults were even more likely to use
CPAP, although the reason for this improved adher-
ence is uncertain. Given that increasing age was asso-
ciated with OSA as well as increased adherence, and
that OSA in older adults is associated with worsening
seizure control or late onset seizures,8 it may be justi-
fiable to target older adults in a future trial of the
effects of treating OSA on epilepsy.
Being a pilot study with a relatively small sample
size, there were inherent limitations present that a
large scale trial will need to address. For example, we
were unable to isolate the effects of specific AEDs on
the presence of sleep apnea. Some seizure types, such
as the idiopathic generalized epilepsies, may be more
sensitive to sleep deprivation and therefore improved
by treatment of a sleep disorder. The severity of sleep
apnea or epilepsy may affect response to treatment.
For safety concerns, we excluded patients with severe
OSA. This selection may have influenced our results;
however, two of our five subjects experiencing a 50%
or greater reduction in seizure frequency on thera-
peutic CPAP had AHIs in the mild range (e.g., five
events/hour). If large scale studies show that treat-
ment of even mild OSA results in seizure reductions
in patients with epilepsy, that would justify including
epilepsy as an associated condition, along with hy-
pertension, cardiac disease, and mood disorders, in
determining whether mild OSA should be treated.
Such studies would also heighten the awareness
among general neurologists and epilepsy specialists
that treating OSA may assist in managing a seizure
disorder. Our study also relied on seizure calendars to
quantify seizures, a methodology which may under-
estimate seizure frequency,31 especially given that pa-
tients with epilepsy with OSA may have more
attention and memory problems than patients with
epilepsy without OSA. In a large scale trial, obtaining
objective monitoring of seizure occurrence may be
warranted.
While large-scale randomized multisite clinical
trials will be necessary to confirm our results, our
findings support a larger evolving literature advocat-
ing the treatment of sleep disorders, including OSA,
in patients with epilepsy and other neurologic dis-
eases.
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